TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-9.4%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.21B
AUM Growth
+$2.21B
(-16%)
Cap. Flow
-$83.2M
Cap. Flow
% of AUM
-3.76%
Top 10 Holdings %
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
77
Closed
10
Top Buys
| 1 |
Biogen
BIIB
|
$15.1M |
| 2 |
Centene
CNC
|
$8.24M |
| 3 |
Moderna
MRNA
|
$7.61M |
| 4 |
Eli Lilly
LLY
|
$6.73M |
| 5 |
Sanofi
SNY
|
$6.15M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$14.8M |
| 2 |
Merck
MRK
|
$14.5M |
| 3 |
MDCO
Medicines Co
MDCO
|
$10.3M |
| 4 |
Johnson & Johnson
JNJ
|
$10.2M |
| 5 |
Pfizer
PFE
|
$8.65M |
Sector Composition
| 1 | Healthcare | 95.66% |
| 2 | Real Estate | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $141M | 6.38% | 1,888,305 -2,271 | -0.1% | -$170K |
|
2
Amgen
AMGN
$155B
| $122M | 5.5% | 599,871 -17,556 | -3% | -$3.56M |
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $116M | 5.23% | 485,730 -8,059 | -2% | -$1.92M |
|
|
4
Johnson & Johnson
JNJ
$427B
| $110M | 4.97% | 838,769 -78,058 | -9% | -$10.2M |
|
|
5
Biogen
BIIB
$19.4B
| $105M | 4.76% | 332,735 +47,609 | +17% | +$15.1M |
|
|
6
Regeneron Pharmaceuticals
REGN
$61.5B
| $83.4M | 3.77% | 170,878 -30,399 | -15% | -$14.8M |
|
|
7
Merck
MRK
$210B
| $78.7M | 3.56% | 1,022,596 -188,788 | -16% | -$14.5M |
|
8
Illumina
ILMN
$15.8B
| $72.5M | 3.28% | 265,319 -7,282 | -3% | -$1.99M |
|
|
9
Pfizer
PFE
$141B
| $59.4M | 2.69% | 1,820,248 -265,100 | -13% | -$8.65M |
|
10
UnitedHealth
UNH
$281B
| $56.6M | 2.56% | 226,827 -22,002 | -9% | -$5.49M |
|
11
Bristol-Myers Squibb
BMY
$96B
| $47.1M | 2.13% | 844,932 +70,070 | +9% | +$3.91M |
|
12
Medtronic
MDT
$119B
| $40.3M | 1.82% | 447,011 -23,801 | -5% | -$2.15M |
|
|
ALXN
13
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $37.1M | 1.68% | 413,326 -22,488 | -5% | -$2.02M |
|
14
Abbott
ABT
$231B
| $36.8M | 1.66% | 466,550 -5,285 | -1% | -$417K |
|
|
15
Eli Lilly
LLY
$657B
| $35.9M | 1.62% | 258,669 +48,488 | +23% | +$6.73M |
|
16
Thermo Fisher Scientific
TMO
$186B
| $31.8M | 1.44% | 112,025 -11,383 | -9% | -$3.23M |
|
17
Incyte
INCY
$16.5B
| $31.7M | 1.43% | 432,246 +49,016 | +13% | +$3.59M |
|
18
CVS Health
CVS
$92.8B
| $29.5M | 1.34% | 497,986 | – | – |
|
|
AGN
19
DELISTED
Allergan plc
AGN
| $28M | 1.26% | 157,981 -1,600 | -1% | -$283K |
|
20
AbbVie
ABBV
$372B
| $26M | 1.17% | 340,916 | – | – |
|
21
Cigna
CI
$80.3B
| $25.3M | 1.14% | 142,655 -47,900 | -25% | -$8.49M |
|
|
SGEN
22
DELISTED
Seagen Inc. Common Stock
SGEN
| $24.8M | 1.12% | 214,530 -62,236 | -22% | -$7.18M |
|
23
BioMarin Pharmaceuticals
BMRN
$11.2B
| $22.9M | 1.03% | 270,613 -5,947 | -2% | -$503K |
|
24
Stryker
SYK
$150B
| $22.6M | 1.02% | 135,795 +22,128 | +19% | +$3.68M |
|
25
Danaher
DHR
$147B
| $22.1M | 1% | 159,352 -6,124 | -4% | -$848K |
|